Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial

Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

“…2 Radiation dermatitis can significantly impose discomfort and interfere with patients' daily living activities and quality of life. 3 Severe toxicity may compromise treatment efficacy if the treatment is interrupted while the injury heals. 4 Hence, it is important to identify approaches aimed at preventing or treating radiation dermatitis in patients with breast cancer.…”

Concurrent use of aromatase inhibitors and hypofractionated radiation therapy

“…Finally, the safety of AI and concurrent adjuvant radiotherapy was prospectively confirmed by the CO-HO-RT study. In this randomized phase Ⅱ study, Azria et al [12] found no increase in skin toxicity in breast cancer patients receiving letrozole and concurrent normofractionated breast radiotherapy, delivering 2 Gy per daily fraction. Of importance, concurrent AI did not influence the efficacy of irradiation at a median follow-up of 26 mo.…”

“…More recently, the prospective randomized phase Ⅱ trial Concomitant Hormono-Radiotherapy (CO-HO-RT) study demonstrated that patients receiving conventionally fractionated RT and letrozole did not experience more frequent or more serious skin toxicity [12] . Although this trial provided evidence for the safety of normofractionated RT and AI, no conclusion could be drawn regarding hypofractionated radiotherapy (HFRT) and concurrent AI.…”

Strahlentherapie

“…Systemtherapie kann die Strahlentherapie auf keinen Fall ersetzen Mögliche Unterschiede in Bezug auf eine Akuttoxizität bei einer sequenziell gegenüber einer simultan zur RT erfolgenden Einnahme des Aromatasehemmers Letrozol wurden bei postmenopausalen Patientinnen in einer randomisierten Studie untersucht und ergaben nach einer mittleren Nachbeobachtungszeit von 26 Monaten keine Unterschiede zwischen den verschiedenen Therapiesequenzen bezüglich therapieassoziierter kutaner Akuttoxizitäten [2,4]. Aussagen zur kardialen Toxizität oder zu Effekten auf das tumorspezifische Überleben sind aufgrund der kurzen Nachbeobachtungsperiode nicht möglich.…”